Skip to main content
Equibles
TMCI logo

TMCI · Treace Medical Concepts, Inc.

Track TMCI — free

Use TMCI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TMCI

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.79 +0.28 (+6.21%) At close · Aug 14
Market Cap
$308.91M
Shares
65.03M

Treace Medical Concepts, Inc. Earnings Call Transcripts

Every quarterly earnings call for Treace Medical Concepts, Inc. (TMCI) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲52.9% $33.05M −$12.13M '22 Q3 22-11-08 ▲48.8% $49.77M −$4.41M '22 Q4 23-03-07 ▲45.3% $42.20M −$13.45M '23 Q1 23-05-08 ▲40% $41.95M −$12.27M '23 Q2 23-08-08 ▲23.3% $40.76M −$17.52M '23 Q3 23-11-09 ▲25% $62.21M −$6.28M '23 Q4 24-02-27 ▲21.1% $51.11M −$18.68M '24 Q1 24-05-07 ▲6% $44.45M −$21.21M '24 Q2 24-08-06 ▲10.6% $45.09M −$15.36M '24 Q3 24-11-05 ▲10.4% $68.71M −$501,000 '24 Q4 25-02-27 ▲2.9% $52.57M −$15.92M '25 Q1 25-05-08 ▲6.6% $47.39M −$17.40M '25 Q2 25-08-07 ▲11.4% $50.21M −$16.29M '25 Q3 25-11-06 ▼9% $62.52M −$9.39M '25 Q4 26-02-26 ▼10.2% $47.20M −$17.96M '26 Q1 26-05-08 LATEST ▼4.2% $45.38M −$15.87M '26 Q2 26-08-07
Earnings call
FY26 · Q2
2026-08-07
Treace Medical Concepts, Inc. Q2 FY2026 Earnings Call
Revenue
$45.38M
▼ 4.2% YoY
Diluted EPS
$-0.24
Gross margin
78.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-08
Treace Medical Concepts, Inc. Q1 FY2026 Earnings Call
Revenue
$47.20M
▼ 10.2% YoY
Diluted EPS
$-0.28
Gross margin
79.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Treace Medical Concepts, Inc. Q4 FY2025 Earnings Call
Positive tone Surgeon base expansion and adoption Cash burn reduction and profitability improvement 2026 mid-year product launches
Revenue
$62.52M*
▼ 9% YoY
Gross margin
80.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Treace Medical Concepts, Inc. Q3 FY2025 Earnings Call
Cautious tone Portfolio expansion and new bunion systems Profitability and cost management 2026 outlook and guidance
Revenue
$50.21M
▲ 11.4% YoY
Diluted EPS
$-0.26
Gross margin
79.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Treace Medical Concepts, Inc. Q2 FY2025 Earnings Call
Confident tone Back-half outlook and seasonality Revenue and financial performance New product launches and expanded portfolio
Revenue
$47.39M
▲ 6.6% YoY
Diluted EPS
$-0.28
Gross margin
79.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Treace Medical Concepts, Inc. Q1 FY2025 Earnings Call
Confident tone New Product Launches (Nanoplasty, PerCuplasty, SpeedMTP) 2025 Full-Year Revenue Guidance Q1 2025 Revenue Performance
Revenue
$52.57M
▲ 2.9% YoY
Diluted EPS
$-0.25
Gross margin
79.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Treace Medical Concepts, Inc. Q4 FY2024 Earnings Call
Positive tone Product portfolio expansion across bunion classes SpeedPlate adoption and fixation mix Foot and ankle expansion opportunities
Revenue
$68.71M*
▲ 10.4% YoY
Gross margin
80.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Treace Medical Concepts, Inc. Q3 FY2024 Earnings Call
Positive tone Nanoplasty 3D MIS system launch 2025 outlook and growth trajectory Lapiplasty core franchise
Revenue
$45.09M
▲ 10.6% YoY
Diluted EPS
$-0.25
Gross margin
80.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Treace Medical Concepts, Inc. Q2 FY2024 Earnings Call
Positive tone R&D pipeline and new product cadence Core Lapiplasty / flagship franchise Minimally invasive osteotomy product launches
Revenue
$44.45M
▲ 6% YoY
Diluted EPS
$-0.34
Gross margin
80.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Treace Medical Concepts, Inc. Q1 FY2024 Earnings Call
Cautious tone MIS Osteotomy Solutions SpeedPlate Platform Product Launches and Pipeline
Revenue
$51.11M
▲ 21.1% YoY
Diluted EPS
$-0.30
Gross margin
80.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Treace Medical Concepts, Inc. Q4 FY2023 Earnings Call
Confident tone Profitability and adjusted EBITDA Revenue growth and market penetration Direct sales channel expansion and productivity
Revenue
$62.21M*
▲ 25% YoY
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Treace Medical Concepts, Inc. Q3 FY2023 Earnings Call
Revenue
$40.76M
▲ 23.3% YoY
Diluted EPS
$-0.28
Gross margin
80.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Treace Medical Concepts, Inc. Q2 FY2023 Earnings Call
Revenue
$41.95M
▲ 40% YoY
Diluted EPS
$-0.20
Gross margin
81.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Treace Medical Concepts, Inc. Q1 FY2023 Earnings Call
Revenue
$42.20M
▲ 45.3% YoY
Diluted EPS
$-0.23
Gross margin
80.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Treace Medical Concepts, Inc. Q4 FY2022 Earnings Call
Revenue
$49.77M*
▲ 48.8% YoY
Gross margin
81.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Treace Medical Concepts, Inc. Q3 FY2022 Earnings Call
Revenue
$33.05M
▲ 52.9% YoY
Diluted EPS
$-0.22
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Treace Medical Concepts, Inc. Q2 FY2022 Earnings Call
Revenue
$29.97M
▲ 45.1% YoY
Diluted EPS
$-0.31
Gross margin
82.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Treace Medical Concepts, Inc. Q1 FY2022 Earnings Call
Revenue
$29.05M
▲ 55.3% YoY
Diluted EPS
$-0.16
Gross margin
82.3%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-12
Treace Medical Concepts, Inc. Q4 FY2021 Earnings Call
Revenue
$33.44M*
▲ 38.7% YoY
Gross margin
83.9%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Treace Medical Concepts, Inc. Q3 FY2021 Earnings Call
Revenue
$21.62M
▲ 51.5% YoY
Diluted EPS
$-0.12
Gross margin
80.4%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Treace Medical Concepts, Inc. Q2 FY2021 Earnings Call
Revenue
$20.65M
▲ 166.9% YoY
Diluted EPS
$-0.10
Gross margin
80.9%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-25
Treace Medical Concepts, Inc. Q1 FY2021 Earnings Call
Revenue
$18.71M
▲ 66.2% YoY
Gross margin
82.2%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts CIK 1630627 CUSIP 89455T109 13F (30d) 117 filings 115 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)